Scarica l'app Stockscreener
5.58
4.78%
-0.28
Pre-mercato:
5.30
-0.28
-5.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie
Atossa Genetics stock surges after FDA rare disease designation By Investing.com - Investing.com South Africa
Atossa Genetics stock surges after FDA rare disease designation - Investing.com
Atossa Therapeutics (ATOS) Secures FDA Designation for Pediatric Treatment - GuruFocus
Atossa gets rare pediatric disease tag for endoxifen in MAS By Investing.com - Investing.com South Africa
FDA awards Atossa Therapeutics rare pediatric designation for Z-endoxifen milestone - Traders Union
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome - PR Newswire
ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
ATOS Should I Buy - Intellectia AI
Atossa Therapeutics (ATOS) price target decreased by 47.43% to 23.46 - MSN
ATOS stock tumbles 32% — here’s what retail investors think of the reverse stock split - MSN
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update - Aktiellt
Atossa Therapeutics joins industry leaders at LSINW2026 to advance cell therapy innovation momentum - Traders Union
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $20 - Moomoo
ATOS Ownership | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Atossa Therapeutics Resolves Endoxifen Patent Disputes, Clarifies Rights - TipRanks
Atossa Therapeutics reaches settlement in Endoxifen patent dispute By Investing.com - Investing.com South Africa
Atossa Therapeutics reaches settlement in Endoxifen patent dispute - Investing.com
Atossa Therapeutics (NASDAQ: ATOS) settles key Endoxifen patent fight - Stock Titan
Atossa Therapeutics (ATOS) price target decreased by 31.37% to 44.62 - MSN
Atossa Therapeutics advances endoxifen as new option for DMD management - Traders Union
ATOS: Ascendiant Capital Lowers Price Target Despite Maintaining 'Buy' Rating | ATOS Stock News - GuruFocus
Atossa Therapeutics, Inc. advances Z-endoxifen pipeline with key U.S. FDA designations into 2026 - Traders Union
Atossa Therapeutics: A 2026 Regulatory Milestone in Sight - AD HOC NEWS
ATOS Stock Eyes Fresh Highs Amid Strong Buying Pressure - Cổng thông tin điện tử Tỉnh Sơn La
Atossa Therapeutics Seeks Shareholder Approval for Further Stock Consolidation - AD HOC NEWS
Atossa (NASDAQ: ATOS) CEO Steven Quay granted 65,000 RSUs after reverse split - Stock Titan
Atossa Therapeutics announces issuance of U.S. patent - MSN
Atossa Therapeutics (ATOS) CFO receives 63,000 RSUs over 3 years - Stock Titan
[ARS] ATOSSA THERAPEUTICS, INC. SEC Filing - Stock Titan
[DEF 14A] ATOSSA THERAPEUTICS, INC. Definitive Proxy Statement - Stock Titan
NCCN event spotlights Atossa Therapeutics, Inc. breast cancer innovation - Traders Union
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
Entry Recap: Is Atossa Therapeutics Inc a speculative investment2026 Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Risk Off: Is Atossa Therapeutics Inc stock heavily shorted2026 Market WrapUp & Accurate Entry/Exit Alerts - baoquankhu1.vn
ATOS Price Today: Atossa Therapeutics, Inc. Stock Price, Quote & Chart - MEXC
H.C. Wainwright raises Atossa Genetics price target to $25 from $7 - Investing.com
ATOS Receives Significant Price Target Increase from HC Wainwrig - GuruFocus
Atossa Therapeutics (ATOS) Sees Increased Price Target Following Stock Split - GuruFocus
Aug Weekly: Is Atossa Therapeutics Incs growth already priced in2026 Decliners & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Atossa Therapeutics Reports 2025 Financial Results and Advances (Z)-Endoxifen in Rare Diseases and Oncology - Minichart
Atossa Therapeutics 2025 Annual Report: (Z)-Endoxifen Clinical Development, Intellectual Property, and Regulatory Strategy - Minichart
Atossa Therapeutics (ATOS) Reports Wider-Than-Expected Loss - GuruFocus
Atossa Genetics Investors to Decide on Key Corporate Proposals - AD HOC NEWS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):